Medtronic plays catch-up in diabetes
The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.
Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Seven plus eight makes six for Globus
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.